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OBJECTIVES: This study aimed at assessing the economic cost
of the management of patients developing herpes zoster (HZ)
and post-herpetic neuralgia (PHN) in France. This is of particular
importance in the context of the marketing of the ﬁrst vaccine
against HZ and PHN (Zostavax®). METHODS: The study is a
cross-sectional cost-of-illness evaluation, led in the perspective of
the French Sickness Funds. Data on health resource utilization
were derived from various private and public databases, the
French DRG system for hospital care and DOREMA™ for
doctors’ visits and drug prescriptions. Utilization data were
valued according to tariffs from public health funds. RESULTS:
HZ life time incidence in France is estimated between 10 and
20% with a yearly incidence of approximately 200,000 cases.
Ten to 20% of these patients will develop PHN. In 2005, there
were 345,000 doctors’ visits related to a HZ or a PHN diagnosis,
86.4% of them being a GP’s visit. Patients with a HZ related
diagnoses were signiﬁcantly older than others (71.3 years vs. 64).
2,643 hospitalizations for a HZ related diagnosis were recorded,
the average length of stay being around 7.5 days. The global
annual cost of HZ and PHN were estimated between 40 and 50
millions Euros. The medication costs represented around 65% of
it, mainly because of the intensive use of antiviral treatments. The
primary care and specialists costs were 7.3 millions euros per
year. Hospitalizations cost accounts for 8.6 millions euros. CON-
CLUSION: This cost evaluation is in line with other foreign
studies results. It is a conservative approach as we use a restric-
tive deﬁnition of hospitalization (HZ or PHN as main diagnose)
and the fact that indirect costs were excluded from the calcula-
tion, as well as quality of life loss which is the most signiﬁcant
consequence for patients experiencing HZ and PHN.
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OBJECTIVES: The incidence of skin and skin structure infec-
tions (SSSIs) due to Staphylococcus aureus (SA) is increasing.
There have been few published studies on the costs of outpatient
treatment for SA-SSSIs. METHODS: This retrospective analysis
used a large managed-care database to assess the duration of
SA-SSSI episodes treated with selected antibiotics (vancomycin,
oral linezolid, and daptomycin, termed “study antibiotics”).
Patients were included if they had a SA-SSSI between January 1,
2002 and December 31, 2005 based on ICD-9-CM codes. Treat-
ment episodes began on the date of the ﬁrst antibiotic and ended
when the patient had fourteen consecutive days with no study
antibiotic or SSSI hospitalization. Costs, represented by health
plan payments, were updated to 2005 US dollars. A generalized
linear model (GLM) was used to assess predictors of costs.
RESULTS: A total of 1,997 patients met the cohort selection
criteria. Mean (SD) age was 46.3 (12.6) and 55.9% of
patients were male. Average episode length was 24 days, and
95% of patients received vancomycin or oral linezolid as their
initial study antibiotic. Patients remained on study antibiotics for
approximately 16 days, and only 5% of patients were switched
to another study antibiotic. Mean (SD) episode costs were
$9,250 ($20,357) [median, $3,327 IQR: $1,643 to $8,128],
represented primarily by pharmacy and outpatient medical ser-
vices. Based on the GLM, we found that treatment failure (i.e.,
study antibiotic switching or hospitalization), bacteremia, osteo-
myelitis, multiple complications, Charlson comorbidity score,
treatment with daptomycin, and episode duration were all sig-
niﬁcant positive predictors of costs. Alternatively, treatment with
oral linezolid, hospitalization prior to receiving a study anti-
biotic, and receipt of a non-study antibiotic before the treatment
episode were signiﬁcant negative predictors of costs. CONCLU-
SION: The costs of treating SA-SSSIs are substantial and vary by
type of antibiotic therapy, comorbidities, and failure rates.
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OBJECTIVES: Chronic hepatitis B (CHB) virus infection afﬂicts
approximately 750,000 people in Spain and if untreated, will
increase their risk of being within the 25–40% of infected indi-
viduals that die of cirrhosis or hepatocellular carcinoma. The
objective of this study was therefore to evaluate the cost-
effectiveness of long-term entecavir therapy of CHB in Spain.
METHODS: Multivariate-adjusted relative risks of disease pro-
gression to liver complications based on viral load categories
were estimated from a large scale epidemiology study
(R.E.V.E.A.L.-HBV) cohort with 42,115 person-years of follow-
up, and applied to efﬁcacy results from separate entecavir and
adefovir clinical trials to project subsequent incidence rates of
compensated cirrhosis (CC), decompensated cirrhosis (DC), and
hepatocellular cancer (HCC). Ofﬁcial drug costs were used for
available antiviral treatments (entecavir, lamivudine and ade-
fovir). Direct medical costs of CHB complications, life expect-
ancy and utility scores for different phases of CHB were derived
from published studies. Viral resistance to drug treatment was
also considered. The perspective was that of the Spanish
National Health System. RESULTS: Head-to-head clinical trials
demonstrated entecavir to be superior to lamivudine for the
proportion of subjects who achieved undetectable viral load in
HBeAg-negative nucleoside-naïve patients, that translated to
lower projected incidence of CHB complications in both the
short (one year) and the long (ten years) term. The modeled costs
and outcomes resulted in incremental cost per QALY gained with
entecavir of €3,578 and €20,502, for 1 and 10 year time horizons
respectively. Using the same approach and an indirect compari-
son of viral suppression efﬁcacy from pivotal clinical trials of
entecavir and adefovir, entecavir was the dominant treatment
option with respect to adefovir in both lamivudine-resistant
patients and HBeAg-positive naïve patients. CONCLUSION:
Long term use of entecavir is a cost-effective alternative to lami-
vudine and adefovir for the management of different subgroups
of CHB patients in Spain.
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